3. TRIALS AND TRIBULATIONS

From The Cancer Chronicles #12
© October, 1992 by Ralph W. Moss, Ph.D.

[LITTLE DID WE KNOW HOW MANY OF HIS "TRIALS" WERE STILL IN THE FUTURE--ED]

In October, the National Cancer Institute (NCI) is scheduled to conduct clinical trials with Dr. S. R. Burzynski's antineoplastons. Antineoplastons are peptides which Burzynski claims constitute a biochemical defense system in the body. NCI has announced that several medical institutions will take part in the trial. Impetus came from an NCI trip last fall, in which site visitors concluded that Burzynski's treatment had indeed successfully shrunk 7 cases of brain tumor.

"We are trying to ascertain in a scientific way," NCI said, "the real value of antineoplastons. Are they of benefit to cancer patients?" There will be 4 independent trials, each involving 25–30 people with different types of brain tumors.

AETNA FIZZLES: In late March, Aetna's five year suit against Burzynski was thrown out of court. This fierce struggle with the insurance giant began in 1986 when the husband of a Burzynski patient sued Aetna for payment of treatment. When Burzynski joined the suit, he was promptly countersued by Aetna for...racketeering!

The fight was bitter and very expensive. When "Dr. B." as he is called got permission in 1989 to test his compounds in people, Aetna asked FDA to revoke this hard-won IND. Aetna also allegedly sent a mass mailing to fellow insurance companies, asking them to no longer reimburse Burzynski's patients.

On March 31, US District Court Judge Kenneth Hoyt threw out Aetna's suit, and simultaneously the patient's original claim.

EMPRISE SURPRISE: When this newsletter began publishing, the most ominous cloud on the horizon was Emprise, Inc., an organization headed by Grace Powers Monaco, Esq., a Washington attorney, who not only aided Aetna in its Burzynski suit but won an NCI grant to compile a data base on `questionable' therapies. After running into a wall of opposition from health activists, and the imminent failure of the Aetna suit, Emprise folded. This spring Monaco announced that Emprise had dissolved last December. Monaco says she has "semi-retired from the practice of law" and is merely consulting on cancer prevention. She remains affiliated with the Candlelighters Childhood Cancer Foundation.

THE JAMA GAME: On June 3, 1992, the Journal of the American Medical Association launched a full-scale attack with an article on Burzynski by Saul Green, PhD, entitled "Antineoplastons—An Unproved Cancer Therapy." JAMA didn't mention that Green was scientific director of Emprise, involved in the Aetna suit. Burzynski has submitted a rebuttal to JAMA with 137 references. [THEY NEVER PUBLISHED IT, ED.]


Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.



home - moss reports - books - - contact - order - news
members - chronicles - faq - free email newsletter